BioLineRx Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- S&P 500, Nasdaq set for subdued open ahead of Fed decision; chip stocks wobble
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Oil jumps nearly 7% on escalating Middle East airstrikes
- Procter & Gamble falls on weak sales, cautious guidance
- Vertiv shares sink as Q2 revenue miss offsets upgraded guidance
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Roth Affirms BioLineRx (BLRX( at 'Buy'; Balance Sheet Strong as BL-8040 Momentum Builds
May 17, 2016 2:15 PM EDTRoth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q1 results reported earlier. BLRX reported Q1 EPS of ($0.10), which was $0.02 worse than the analyst estimate of ($0.08).
Analyst Joseph Pantginis commented, BL-8040 continues to be the lead value driver with initial positive data in r/rAML, an ongoing Phase II in consolidation AML and positive stem cell... More
